Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Forteo Prescribers (US)(?)

Council Members in this Study Group: 58

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Ara Dikranian, MD
Partner
San Diego Arthritis Medical Clinic

Ara Dikranian, MD, is a Rheumatologist at San Diego Arthritis Medical Clinic, a single-specialty private practice in San Diego, California. Dr. Dikranian is board certified in Internal Medicine and Rheumatology. He completed his rheumatology training at the University of California San Diego. He has...

Dipti Doshi, MD
Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP

Dipti Doshi, MD, is a board certified Rheumatologist at Health Care Partners Medical group, California. Dr. Doshi is also board certified in Internal Medicine. Her special interests are in rheumatoid arthritis, lupus, pain-related to scleroderma, fibromyalgia, and osteoarthritis. Dr. Doshi is interested...

David Portman, MD, Director, Columbus Center For Womens Health Research David Portman, MD
Director
Columbus Center For Womens Health Research

David Portman, MD, is Director and Principal Investigator of the Columbus Center for Women's Health Research. Dr. Portman is also a Clincial Investigator at The Ohio State University. He has conducted over 100 clinical studies in areas of contraception, osteoporosis, menopause, and sexual dysfunction...

Farhad Zangeneh, MD, Assistant Clinical Professor of Medicine , THE GEORGE WASHINGTON UNIVERSITY - CCFarhad Zangeneh, MD
Assistant Clinical Professor of Medicine
THE GEORGE WASHINGTON UNIVERSITY - CC

Farhad Zangeneh, MD, is an Assistant Clinical Professor of Medicine at George Washington University School of Medicine in District of Columbia. He is on the board of directors of ACCE and recently contributed to the AACE Diabetes guidelines. He is the Medical Director of Endocrine, Diabetes and Osteoporosis...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com

 Should bisphosphonates be stopped in patients who have been taking them for many years?  Should they be used at all?

May 28, 2008
Tekturna scripts

I am a heavy user of ARB's and Tekturna.  This article does not really show anything of significance.  Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...

By Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...

Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk

-the relationship between avandia and ostoeporosis -implcations in clinical practice -implications for the future of avandia

October 22, 2007
Pfizer abandons exubera

Due to poor sales, Pfizer has decided to pull the plug on Exubera (inhaled insulin).  This will have a signficant impact on other companies who are developing other inhaled insulin products.

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Other Freestanding Healthcare Facility
  • Academic Institution*

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • Director
  • Partner
  • President
  • Physician - Division Head

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880